The collaboration expands and diversifies the Oliva product portfolio while representing the first commercialization into the United States and Canadian markets for Rio Biopharmaceuticals, expanding upon the organization’s global presence.
Daniel Akeson, CEO of Olivia Therapeutics, said: “Oliva Therapeutics is excited and honored to have been selected as the exclusive partner for this unique and high-value portfolio of products.”
“The Rio Biopharmaceuticals team and EMS have developed an incredible global infrastructure with a thoughtful portfolio that offers quality and value.”
Daniel Salazar, CEO of Rio Biopharmaceuticals, added: “Rio Biopharmaceuticals, and the EMS Pharma organization, have a tremendous history of delivering high-quality, cost-conscious pharmaceuticals throughout the world.”
“Entering into the North American markets represents an important step in our growth and evolution, and partnering with a family-owned company in Oliva Therapeutics ensures that our culture and values are well represented.”
The portfolio anticipates initial product commercialization in 2024 followed by additional launches over the succeeding 24-months.